Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG)

被引：0
|
作者：
Al-Sawaf, O. [1 ]
Kluth, S. [1 ]
Bahlo, J. [1 ]
Hopfinger, G. [2 ]
Fink, A. M. [1 ]
Cramer, P. [1 ]
Maurer, C. [1 ]
Bergmann, M. [3 ]
Dreyling, M. [4 ]
Lange, E. [5 ]
Kneba, M. [6 ]
Stilgenbauer, S. [7 ]
Kiehl, M. G. [8 ]
Jaeger, U. [9 ]
Wendtner, C. M. [3 ]
Fischer, K. [1 ]
Hallek, M. [1 ,10 ]
Eichhorst, B. [1 ]
机构：
[1] Uniklin Koln, Ctr Integrierte Onkol Koln Bonn, Klin Innere Med 1, Deutsch CLL Studiengrp, Cologne, Germany
[2] Med Univ Wien, Univ Klin Innere Med 1, Vienna, Austria
[3] Klinikum Munchen Schwabing, Klin Hamatol Onkol Immunol Palliat Med Infektiol, Munich, Germany
[4] Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany
[5] Evangel Krankenhaus Hamm, Klin Hamatol Onkol & Palliat Med, Hamm, Germany
[6] Univ Klinikum Schleswig Holstein, Klin Hamatol Onkol & Palliat Med, Kiel, Germany
[7] Uniklin Ulm, Klin Innere Med 3, Ulm, Germany
[8] Klinikum Frankfurt Oder, Med Klin 1, Frankfurt, Oder, Germany
[9] Allgemeines Krankenhaus Wien, Klin Abt Hamatol & Hamostaseol, Vienna, Austria
[10] Uniklin Koln, CECAD Cluster Excellence Cellular Stress Response, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V685
引用
收藏
页码：212 / 213
页数：2
相关论文
共 50 条
  • [41] Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).
    Batty, Nicolas
    Badoux, Xavier C.
    Keating, Michael
    Lin, E.
    Lerner, Susan
    O'Brien, Susan
    Ferrajoli, Alessandra
    Kadia, Tapan
    Burger, Jan A.
    Faderl, Stefan
    Wierda, William G.
    BLOOD, 2009, 114 (22) : 1339 - 1340
  • [42] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL study group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [43] Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group
    Elter, T.
    James, R.
    Wendtner, C. M.
    Stilgenbauer, S.
    Winkler, D.
    Ritgen, M.
    Hallek, M.
    Engert, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)
    Kutsch, Nadine
    Bottcher, Sebastian
    Robrecht, Sandra
    Bahlo, Jasmin
    Maurer, Christian
    Lange, Elisabeth
    Koppler, Hubert
    Kiehl, Michael G.
    Sokler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Kochling, Georg
    Ploger, Christoph
    Gregor, Michael
    Plesner, Torben
    Oschlies, Ilske
    Herling, Marco
    Fischer, Kirsten
    Dohner, Hartmut
    Kneba, Michael
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Fink, Anna Maria
    Hallek, Michael
    Klapper, Wolfram
    Eichhorst, Barbara F.
    BLOOD, 2017, 130
  • [45] Immune Recovery Refines the Prognostic Impact of Minimal Residual Disease on Overall and Progression Free Survivals after Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in CLL Patients
    Gauthier, Martin
    Durrieu, Florence
    Peres, Michael
    Martin, Elodie
    Filleron, Thomas
    Recher, Christian
    Mary, Anne Quillet
    Ysebaert, Loic
    BLOOD, 2017, 130
  • [46] Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: Results of a phase 2 study.
    Faderl, Stefan
    Wierda, William G.
    O'Brien, Susan
    Ferrajoli, Alessandra
    Ravandi-Kashani, Farhad
    Detry, Michelle
    Kantarjian, Hagop M.
    O'Neal, Brandi
    Keating, Michael J.
    BLOOD, 2006, 108 (11) : 803A - 803A
  • [47] Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab - a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial
    Boettcher, Sebastian
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Busch, Raymonde
    Fingerle-Rowson, Guenter
    Fink, Anna-Maria
    Doehner, Hartmut
    Hallek, Michael
    Kneba, Michael
    Ritgen, Matthias
    BLOOD, 2008, 112 (11) : 125 - 126
  • [48] First-line treatment and outcome in patients with chronic lymphocytic leukemia (CLL) according to age: a report of the German CLL Study Group (GCLLSG) registry
    Maurer, C.
    Fink, A. M.
    Robrecht, S.
    Bahlo, J.
    Fischer, K.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 170 - 171
  • [49] Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study
    Herishanu, Yair
    Levi, Shai
    Goldschmidt, Neta
    Morabito, Fortunato
    Bairey, Osnat
    Del Poeta, Giovanni
    Baran, Tomer Ziv
    Fineman, Riva
    Mauro, Francesca Romana
    Gutwein, Odit
    Reda, Gianluigi
    Ruchlemer, Rosa
    Sportoletti, Paolo
    Laurenti, Luca
    Shvidel, Lev
    Coscia, Marta
    Tadmor, Tamar
    Varettoni, Marzia
    Aviv, Ariel
    Murru, Roberta
    Breaster, Andrei
    Bronstein, Yotam
    Chiarenza, Annalisa
    Visentin, Andrea
    Pietrasanta, Daniela
    Loseto, Giacomo
    Zucchetto, Antonella
    Bomben, Riccardo
    Olivieri, Jacopo
    Neri, Antonino
    Rossi, Davide
    Gaidano, Gianluca
    Trentin, Livio
    Foa, Robin
    Cuneo, Antonio
    Gattei, Valter
    Gentile, Massimo
    BLOOD, 2021, 138
  • [50] Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study
    Egle, Alexander
    Weiss, Lukas
    Melchardt, Thomas
    Gunsilius, Eberhard
    Petzer, Andreas L.
    Fridrik, Michael
    Lang, Alois
    Krieger, Otto
    Thaler, Josef
    Greil, Richard
    BLOOD, 2010, 116 (21) : 593 - 594
12345